Navigation Links
Amarin Signs Agreement to Acquire Ester Neurosciences
Date:12/5/2007

rice of $1.00 and thus to regain and sustain compliance with this requirement.

Amarin received a notice on December 4, 2007 from The Nasdaq Stock Market indicating that the Company is not in compliance with the $1.00 minimum bid requirement for continued listing and, as a result, the Company's ADSs are subject to delisting, unless the Company requests a hearing by December 11, 2007 in accordance with the Nasdaq Marketplace Rules. The Company intends to request an appeal hearing prior to December 11, 2007 with the Nasdaq Listing Qualification Panel to review the delisting determination. There can be no assurance that the Panel will grant the Company's request for continued listing. If the Panel denies the request, the Company's ADSs will be delisted. The hearing date will be determined by Nasdaq and should occur within 45 calendar days from the request for hearing. Amarin's hearing request will 'stay' the delisting of the Company's ADSs pending the Panel's decision. At the hearing, the Company will be required to provide a plan to regain compliance with the minimum bid price requirement, which will include the Company's plan to seek shareholder approval for the reverse stock split in order to exceed the minimum bid price requirement.

This press release does not constitute a solicitation of proxies for any meeting of shareholders, which can only be made by way of a properly filed meeting notice and related proxy form.

For further information regarding the financial impact of the Ester acquisition on Amarin's historical financial statements, please see the unaudited historical pro forma condensed combined financial statements filed with the SEC in a Report of Foreign Issuer on Form 6-K and available on our website; http://www.amarincorp.com.

Myasthenia Gravis - An Unmet Medical Need

MG is the most common primary disorder of neuromuscular transmission. It is a chronic autoimmune neu
'/>"/>

SOURCE Amarin Corporation Plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
2. Amarin to Present at 4th Annual Bio Investor Forum
3. Amarin Announces Initiation of Cardiovascular Development Strategy
4. Amarin Corporation to Present at Acumen BioFin Rodman & Renshaw Ninth Annual Healthcare Conference
5. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
6. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
7. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
8. Monsanto Company Signs Share Subscription Agreement With Devgen
9. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
10. Shandong Zhouyuan Seed and Nursery Co., Ltd. Signs an Agreement with Linyi Company
11. Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. ... Road, Warrington, Pa. , Details: The Hepatitis B ... a cure for hepatitis B and improving the quality of ... Ball on Friday, April 11 at Warrington Country Club in ...
(Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
(Date:1/14/2014)... Mass. , Jan. 14, 2014  RXi Pharmaceuticals ... discovering, developing and commercializing innovative therapies addressing major ... that it received the Notice of Allowance from ... its unique self-delivering RNAi compounds (sd-rxRNA®), for the ...
(Date:1/14/2014)... 14, 2014 During the 1600’s through the ... “The Doctor’s Plague.” In this time period, doctors did not ... at times, to the death of vulnerable patients. In the ... that they may be unwittingly transmitting herpes viruses to their ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... movie about giant robots that undergo structural ... a scientific study about structural transformations within single ... of novel materials that will serve next-generation energy ... at the U.S. Department of Energy (DOE),s Lawrence ...
... 8, 2011 Northwest Biotherapeutics (OTC Bulletin Board: ... equity investment on June 28, 2011, by The Richard ... newly issued common stock of the Company to the ... 31, 2011, by investment funds managed by Whitebox Advisors, ...
... 7, 2011 For the first time since stem ... isolated a human blood stem cell in its purest ... regenerating the entire blood system. This breakthrough opens the ... to treat cancer and other debilitating diseases more effectively. ...
Cached Biology Technology:Nanocrystal transformers 2Nanocrystal transformers 3Nanocrystal transformers 4Family Foundation of Business Leader Invests $4.55 Million in Northwest Biotherapeutics for Promising Clinical Trials in the US and Europe 2Family Foundation of Business Leader Invests $4.55 Million in Northwest Biotherapeutics for Promising Clinical Trials in the US and Europe 3Family Foundation of Business Leader Invests $4.55 Million in Northwest Biotherapeutics for Promising Clinical Trials in the US and Europe 4"Pure" Human Blood Stem-Cell Discovery Opens Door to Expanding Cells for More Clinical Use 2"Pure" Human Blood Stem-Cell Discovery Opens Door to Expanding Cells for More Clinical Use 3
(Date:4/17/2014)... to produce hydrogen sulfide in order to properly multiply ... from the Center for Craniofacial Molecular Biology at the ... Songtao Shi, principal investigator on the project, said the ... the flow of calcium ions. The essential ions activate ... or the creation of new bone tissue, and keeps ...
(Date:4/17/2014)... release is available in German . ... pay the protection money demanded of him, he can expect ... required, however, as fear of the consequences is enough to ... in parasitic birds, which lay their eggs in other birds, ... the brood parasites take their revenge by destroying the entire ...
(Date:4/17/2014)... have hit on a novel method to help ... and most effective treatment possible., Kidney stones represent ... developing world. If left untreated, apart from being ... and other complications. In many patients treated successfully, ... more effective pathological approach to diagnosis and treatment ...
Breaking Biology News(10 mins):Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3
... 2004, Washington University in St. Lous researcher Jianmin Cui was ... channel his lab had been studying for five years. ... a large family whose members suffered from epilepsy, sudden attacks ... and paroxysmal dyskinesia (GEPD). By analyzing the DNA of ...
... attacks in the United States are fostering development of ... to protect people against the potentially deadly bacteria in ... sweeping overview of scientific research on medical technology to ... Journal of Medicinal Chemistry . In ...
... are reporting that particle size affects the toxicity of zinc ... 100 nanometers are slightly more toxic to colon cells than ... equivalent amounts of soluble zinc, and direct particle to cell ... in ACS, Chemical Research in Toxicology , a monthly ...
Cached Biology News:Solving the puzzle of the BK ion channel 2Solving the puzzle of the BK ion channel 3Solving the puzzle of the BK ion channel 4Solving the puzzle of the BK ion channel 5New medical weapons to protect against anthrax attacks 2
MpV17 transgene, murine homolog, glomerulosclerosis...
Mouse monoclonal [6C3] to JAB1 ( Abpromise for all tested applications). entrezGeneID: 10987 SwissProtID: O15386...
Recombinant Ovine (Sheep) Prolactin, Ultra Pure...
Human LT beta R/TNFRSF3 Phycoerythrin MAb (Clone 71319)...
Biology Products: